000 01262 a2200337 4500
005 20250513191727.0
264 0 _c19991012
008 199910s 0 0 eng d
022 _a0899-823X
024 7 _a10.1086/501669
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aCieslak, P R
245 0 0 _aVancomycin in Oregon: who's using it and why.
_h[electronic resource]
260 _bInfection control and hospital epidemiology
_cAug 1999
300 _a557-60 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650 0 4 _aAnti-Bacterial Agents
650 0 4 _aCross Infection
_xprevention & control
650 0 4 _aDrug Prescriptions
_xstatistics & numerical data
650 0 4 _aDrug Resistance, Microbial
650 0 4 _aGuideline Adherence
650 0 4 _aHumans
650 0 4 _aPharmacy Service, Hospital
_xstandards
650 0 4 _aPractice Patterns, Physicians'
650 0 4 _aVancomycin
_xtherapeutic use
700 1 _aStrausbaugh, L J
700 1 _aFleming, D W
700 1 _aLing, J M
773 0 _tInfection control and hospital epidemiology
_gvol. 20
_gno. 8
_gp. 557-60
856 4 0 _uhttps://doi.org/10.1086/501669
_zAvailable from publisher's website
999 _c10424084
_d10424084